TY  - JOUR
AU  - Sachpekidis, Christos
AU  - Stein-Thoeringer, Christoph K
AU  - Kopp-Schneider, Annette
AU  - Weru, Vivienn
AU  - Dimitrakopoulou-Strauss, Antonia
AU  - Hassel, Jessica C
TI  - Can physiologic colonic [18F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?
JO  - European journal of nuclear medicine and molecular imaging
VL  - 50
IS  - 12
SN  - 1619-7070
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - DKFZ-2023-01448
SP  - 3709-3722
PY  - 2023
N1  - #EA:E060#LA:E060# / 2023 Oct;50(12):3709-3722
AB  - The development of biomarkers that can reliably and early predict response to immune checkpoint inhibitors (ICIs) is crucial in melanoma. In recent years, the gut microbiome has emerged as an important regulator of immunotherapy response, which may, moreover, serve as a surrogate marker and prognosticator in oncological patients under immunotherapy. Aim of the present study is to investigate if physiologic colonic [18F]FDG uptake in PET/CT before start of ICIs correlates with clinical outcome of metastatic melanoma patients. The relation between [18F]FDG uptake in lymphoid cell-rich organs and long-term patient outcome is also assessed.One hundred nineteen stage IV melanoma patients scheduled for immunotherapy with ipilimumab, applied either as monotherapy or in combination with nivolumab, underwent baseline [18F]FDG PET/CT. PET/CT data analysis consisted of standardized uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) calculations in the colon as well as measurements of the colon-to-liver SUV ratios (CLRmean, CLRmax). Visual grading of colon uptake based on a four-point scale was also performed. Moreover, the spleen-to-liver SUV ratios (SLRmean, SLRmax) and the bone marrow-to-liver SUV ratios (BLRmean, BLRmax) were calculated. We also measured serum lipopolysaccharide (LPS) levels as a marker for bacterial translocation and surrogate for mucosal defense homeostasis. The results were correlated with patients' best clinical response, progression-free survival (PFS), and overall survival (OS) as well as clinical signs of colitis.Median follow-up [95
KW  - Gut microbiome (Other)
KW  - Immunotherapy (Other)
KW  - Lipopolysaccharide (LPS) (Other)
KW  - MTV (Other)
KW  - Metastatic melanoma (Other)
KW  - PET/CT (Other)
KW  - SUV (Other)
KW  - TLG (Other)
KW  - [18F]FDG colonic uptake (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37452874
DO  - DOI:10.1007/s00259-023-06327-9
UR  - https://inrepo02.dkfz.de/record/277731
ER  -